Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Involving "authentic" cancer patients, their caregivers, and multidisciplinary professionals in a quality improvement trajectory in a hospital cancer pathway: a study protocol.

Melchior I, Moser A, Veenstra MY, Jie KS.

J Multidiscip Healthc. 2018 Nov 9;11:661-671. doi: 10.2147/JMDH.S177957. eCollection 2018.

2.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
3.

A conversation approach based on shared goal-setting and shared decision-making for nurses in cancer aftercare: A developmental study.

Friesen-Storms JH, Bours GJ, Snijders IC, van der Weijden T, Jie KG, Beurskens AJ.

Eur J Oncol Nurs. 2018 Aug;35:107-116. doi: 10.1016/j.ejon.2018.06.002. Epub 2018 Jul 11.

4.

Intermediate and nonclassical monocytes show heterogeneity in patients with different types of acute coronary syndrome.

Leers MPG, Stockem C, Ackermans D, Loeffen R, Ten Cate H, Kragten JA, Jie KG.

Cytometry A. 2017 Nov;91(11):1059-1067. doi: 10.1002/cyto.a.23263. Epub 2017 Oct 11.

5.

[A man with a primary diffuse B-cell lymphoma of the bone].

Wanrooij VH, Jie KS.

Ned Tijdschr Geneeskd. 2017;161:D1193. Dutch.

PMID:
28378702
6.

[Erythema after subcutaneous heparin treatment].

Brouns AJ, Jie KS.

Ned Tijdschr Geneeskd. 2015;159:A9304. Dutch.

PMID:
26507065
7.

Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics.

Stienen JJ, Hermens RP, Wennekes L, van de Schans SA, van der Maazen RW, Dekker HM, Liefers J, van Krieken JH, Blijlevens NM, Ottevanger PB; PEARL study group.

BMC Cancer. 2015 Aug 8;15:578. doi: 10.1186/s12885-015-1547-8.

8.

Trends in quality of non-Hodgkin's lymphoma care: is it getting better?

Stienen JJ, Ottevanger PB, Wennekes L, van de Schans SA, Dekker HM, van der Maazen RW, van Krieken JH, Blijlevens NM, Hermens RP; PEARL study group.

Ann Hematol. 2015 Jul;94(7):1195-203. doi: 10.1007/s00277-015-2340-0. Epub 2015 Mar 15.

9.

Concentrated citrate locking in order to reduce the long-term complications of central venous catheters: a randomized controlled trial in patients with hematological malignancies.

Boersma RS, Jie KS, Voogd AC, Hamulyak K, Verbon A, Schouten HC.

Support Care Cancer. 2015 Jan;23(1):37-45. doi: 10.1007/s00520-014-2320-2. Epub 2014 Jun 20.

PMID:
24947057
10.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

11.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P.

N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.

12.

The pro- and anticoagulant role of blood-borne phagocytes in patients with acute coronary syndrome.

Leers MP, Keuren JF, Frissen ME, Huts M, Kragten JA, Jie KS.

Thromb Haemost. 2013 Jul;110(1):101-9. doi: 10.1160/TH12-09-0643. Epub 2013 Apr 18.

PMID:
23595567
13.

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators.

N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697.

14.

Atypical polyarthritis as a major manifestation of light chain disease.

Van Landuyt KB, Starmans MJ, Peeters RM, Jie KS.

Ann Hematol. 2012 Oct;91(10):1653-5. doi: 10.1007/s00277-012-1446-x. Epub 2012 Mar 14. No abstract available.

PMID:
22411185
15.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.

Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.

PMID:
21981697
16.

In vivo and in vitro antitumor effects of a staphylococcal enterotoxin A mutant (SEA-H61D).

Wang HR, Jiang H, Hao HJ, Zheng YL, Jie KG, Gu J, Jiang YQ.

Cancer Invest. 2010 Oct;28(8):788-96. doi: 10.3109/07357900903286982.

PMID:
20504220
17.

[Interstitial pneumonitis as an adverse effect of thalidomide].

Scholte JB, Potjewijd J, Voogt PJ, Custers FL, Jie KS.

Ned Tijdschr Geneeskd. 2009;153:A452. Dutch.

PMID:
20051154
18.

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON).

Blood. 2010 Feb 11;115(6):1113-20. doi: 10.1182/blood-2009-05-222539. Epub 2009 Oct 30.

19.

Increased expression of TF on monocytes, but decreased numbers of TF bearing microparticles in blood from patients with acute myocardial infarction.

Keuren JF, Jie KS, Leers MP.

Eur J Haematol. 2009 Oct;83(4):387-8. doi: 10.1111/j.1600-0609.2009.01306.x. Epub 2009 Jun 25. No abstract available.

PMID:
19558505
20.

Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis.

Smalberg JH, Spaander MV, Jie KS, Pattynama PM, van Buuren HR, van den Berg B, Janssen HL, Leebeek FW.

Thromb Haemost. 2008 Dec;100(6):1084-8.

PMID:
19132234

Supplemental Content

Loading ...
Support Center